环状RNA hsa-circ-0015022作为胰腺癌新型诊断生物标志物研究  

Research of hsa-circ-0015022 as a new diagnostic biomarker for pancreatic cancer

作　　者：王赫[1] 刘冬妍[1] 王晟[1] 郭瑾陶[1] 刘香[1] 葛楠[1] 王国鑫[1] 杨帆[1] 孙思予[1] WANG He;LIU Dong-yan;WANG Sheng;GUO Jin-tao;LIU Xiang;GE Nan;WANG Guo-xin;YANG Fan;SUN Si-yu(Department of Gastroenterology,Shengjing Hospital of China Medical University,Shenyang 110004,China)

机构地区：[1]中国医科大学附属盛京医院消化内科,辽宁沈阳110004

出　　处：《临床军医杂志》2020年第1期30-34,共5页Clinical Journal of Medical Officers

基　　金：辽宁省自然科学基金(20180530014);辽宁省博士启动基金(2019-BS-276);沈阳市科技计划项目(19-112-4-103);中国医科大学青年骨干支持计划(QGZ2018058)。

摘　　要：目的从胰腺癌患者血液和胰腺癌组织两方面分析,探讨hsa-circ-0015022作为胰腺癌诊断生物标志物的可行性。方法选择胰腺癌组织30例、相应的癌旁组织30例(对照组)作为研究用的组织标本。选择胰腺癌患者血液标本30例,健康志愿者血液标本30例(对照组)作为研究用的血液标本。使用实时荧光定量聚合酶链式反应检验hsa-circ-0015022的表达情况。临床病理数据用于分析该指标与胰腺癌患者年龄、性别、肿瘤直径、血清CEA水平、临床分期、临床病理(TNM)分期、血管受侵以及淋巴受侵等的相关性。结合CA19-9,探讨hsa-circ-0015022能否作为胰腺癌诊断的生物标志物。结果与各自对照组比较,hsa-circ-0015022在胰腺癌组织以及胰腺癌患者血液中均高表达(P <0. 05)。组织样本的临床病理数据分析显示,hsa-circ-0015022的表达情况与临床分期、TNM分期中的N分期及淋巴受侵有关(P <0. 05);血液样本的临床病理数据分析显示,hsa-circ-0015022的表达情况与TNM分期中的N分期及血清CA19-9水平有关(P <0. 05)。单独使用hsa-circ-0015022的诊断效率:受试者工作特征曲线(ROC)下面积0. 70,临界值10. 17,敏感性0. 623 0,特异性0. 709 7。hsa-circ-0015022联合CA19-9的诊断效率:ROC曲线下面积增至0. 85,敏感性增至0. 770 5,特异性增至0. 838 7。结论 hsa-circ-0015022高表达的情况在胰腺癌组织及胰腺癌患者血液中均存在,而且可能与TNM分期中的N分期有关。hsa-circ-0015022与CA19-9联合使用,可能会作为生物标志物,用于协助诊断胰腺癌,尤其是协助诊断胰腺癌的N分期情况。Objective To investigate the feasibility of hsa-circ-0015022 as a biomarker for the diagnosis of pancreatic cancer from the perspective of blood and tissue of pancreatic cancer patients. Methods The 30 cases of pancreatic cancer and 30 cases of corresponding adjacent tissues( control group) were selected as tissue samples for the study. The 30 blood samples from pancreatic cancer patients and 30 blood samples from healthy volunteers( control group) were selected as blood samples for the study. The expression of hsa-circ-0015022 was determined by Real-time fluorescent quantitative polymerase chain reaction. The clinicopathological data were used to analyze the correlation between this index and age,gender,tumor diameter,serum CEA level,clinical stage,tumor node metastasis( TNM)stage,vascular invasion and lymphatic invasion of pancreatic cancer patients. Combined with CA19-9,whether hsa-circ-0015022 could be used as a biomarker for the diagnosis of pancreatic cancer. Results Compared with the control group,respectively,hsa-circ-0015022 was highly expressed in pancreatic cancer tissues and blood of pancreatic cancer patients( P < 0. 05). The clinicopathological analysis of the tissue samples showed that the expression of hsa-circ-0015022 was related to clinical staging,N staging in TNM staging and lymphatic invasion( P < 0. 05). The clinicopathological analysis of blood samples showed that the expression of hsa-circ-0015022 was related to the N stage of TNM stage and the serum CA19-9 level( P < 0. 05). Diagnostic efficiency of hsa-circ-0015022 alone: subject operating characteristic curve( ROC) area 0. 70,threshold 10. 17,sensitivity 0. 623 0,specificity 0. 709 7. Diagnostic efficiency of hsa-circ-0015022 combined with CA19-9: area under the ROC curve increased to 0. 85,sensitivity increased to 0. 770 5,and specificity increased to 0. 838 7. Conclusion The high expression of hsa-circ-0015022 is found in pancreatic cancer tissues and blood of pancreatic cancer patients,and may be related to the N stage of TNM stage.

关 键 词：胰腺癌 诊断标记物 环状RNA hsa-circ-0015022 

分 类 号：R735.9[医药卫生—肿瘤]